vs
CATALYST PHARMACEUTICALS, INC.（CPRX）とONESPAWORLD HOLDINGS Ltd（OSW）の財務データ比較。上の社名をクリックして会社を切り替えられます
ONESPAWORLD HOLDINGS Ltdの直近四半期売上が大きい（$242.1M vs $152.6M、CATALYST PHARMACEUTICALS, INC.の約1.6倍）。CATALYST PHARMACEUTICALS, INC.の純利益率が高く（34.5% vs 5.0%、差は29.5%）。ONESPAWORLD HOLDINGS Ltdの前年同期比売上増加率が高い（11.5% vs 7.6%）。CATALYST PHARMACEUTICALS, INC.の直近四半期フリーキャッシュフローが多い（$44.9M vs $14.9M）。過去8四半期でCATALYST PHARMACEUTICALS, INC.の売上複合成長率が高い（24.5% vs 7.1%）
Catalyst Pharmaceuticalsは米国フロリダ州コーラルゲーブルズに本拠を置くバイオ医薬品企業で、希少疾患向け治療薬の開発を事業の核心としています。主力品にランバート・イートン筋無力症候群（LEMS）治療薬のアミファンプリジンリン酸塩（商品名Firdapse）があり、2018年11月のFDA承認により、既存の成人に加え6歳以上の小児LEMS患者への投与も認められました。
CPRX vs OSW — 直接比較
損益計算書 — Q4 FY2025 vs Q4 FY2025
| 指標 | | |
|---|---|---|
| 売上 | $152.6M | $242.1M |
| 純利益 | $52.7M | $12.1M |
| 粗利率 | 82.9% | — |
| 営業利益率 | 40.5% | 6.8% |
| 純利益率 | 34.5% | 5.0% |
| 売上前年比 | 7.6% | 11.5% |
| 純利益前年比 | -5.8% | -16.2% |
| EPS（希薄化後） | $0.40 | $0.12 |
緑 = その指標でリード。会計年度がずれている場合は期間が異なる場合あり
8四半期 売上・利益トレンド
並べて比較する四半期履歴。決算期がずれていても暦四半期で整列
| Q4 25 | $152.6M | $242.1M | ||
| Q3 25 | $148.4M | $258.5M | ||
| Q2 25 | $146.6M | $240.7M | ||
| Q1 25 | $141.4M | $219.6M | ||
| Q4 24 | $141.8M | $217.2M | ||
| Q3 24 | $128.7M | $241.7M | ||
| Q2 24 | $122.7M | $224.9M | ||
| Q1 24 | $98.5M | $211.2M |
| Q4 25 | $52.7M | $12.1M | ||
| Q3 25 | $52.8M | $24.3M | ||
| Q2 25 | $52.1M | $19.9M | ||
| Q1 25 | $56.7M | $15.3M | ||
| Q4 24 | $55.9M | $14.4M | ||
| Q3 24 | $43.9M | $21.6M | ||
| Q2 24 | $40.8M | $15.8M | ||
| Q1 24 | $23.3M | $21.2M |
| Q4 25 | 82.9% | — | ||
| Q3 25 | 84.7% | — | ||
| Q2 25 | 85.9% | — | ||
| Q1 25 | 87.3% | — | ||
| Q4 24 | 84.7% | — | ||
| Q3 24 | 85.0% | — | ||
| Q2 24 | 87.4% | — | ||
| Q1 24 | 87.3% | — |
| Q4 25 | 40.5% | 6.8% | ||
| Q3 25 | 44.7% | 10.2% | ||
| Q2 25 | 45.2% | 9.2% | ||
| Q1 25 | 44.8% | 7.7% | ||
| Q4 24 | 44.3% | 7.9% | ||
| Q3 24 | 39.6% | 10.3% | ||
| Q2 24 | 44.2% | 8.4% | ||
| Q1 24 | 27.5% | 8.0% |
| Q4 25 | 34.5% | 5.0% | ||
| Q3 25 | 35.6% | 9.4% | ||
| Q2 25 | 35.6% | 8.3% | ||
| Q1 25 | 40.1% | 7.0% | ||
| Q4 24 | 39.4% | 6.6% | ||
| Q3 24 | 34.1% | 8.9% | ||
| Q2 24 | 33.2% | 7.0% | ||
| Q1 24 | 23.6% | 10.0% |
| Q4 25 | $0.40 | $0.12 | ||
| Q3 25 | $0.42 | $0.23 | ||
| Q2 25 | $0.41 | $0.19 | ||
| Q1 25 | $0.45 | $0.15 | ||
| Q4 24 | $0.44 | $0.13 | ||
| Q3 24 | $0.35 | $0.20 | ||
| Q2 24 | $0.33 | $0.15 | ||
| Q1 24 | $0.19 | $0.21 |
貸借対照表と財務力
直近四半期の流動性・レバレッジ・純資産のスナップショット
| 指標 | | |
|---|---|---|
| 現金・短期投資手元流動性 | $709.2M | $16.3M |
| 総負債低いほど良い | — | $84.0M |
| 株主資本純資産 | $954.3M | $542.6M |
| 総資産 | $1.1B | $707.1M |
| 負債/資本比率低いほどレバレッジが低い | — | 0.15× |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $709.2M | $16.3M | ||
| Q3 25 | $689.9M | $29.6M | ||
| Q2 25 | $652.8M | $35.0M | ||
| Q1 25 | $580.7M | $22.6M | ||
| Q4 24 | $517.6M | $57.4M | ||
| Q3 24 | $442.3M | $48.8M | ||
| Q2 24 | $375.7M | $62.5M | ||
| Q1 24 | $310.4M | $65.4M |
| Q4 25 | — | $84.0M | ||
| Q3 25 | — | $85.2M | ||
| Q2 25 | — | $96.2M | ||
| Q1 25 | — | $97.4M | ||
| Q4 24 | — | $98.6M | ||
| Q3 24 | — | $98.7M | ||
| Q2 24 | — | $123.8M | ||
| Q1 24 | — | $138.6M |
| Q4 25 | $954.3M | $542.6M | ||
| Q3 25 | $920.2M | $552.8M | ||
| Q2 25 | $856.0M | $548.3M | ||
| Q1 25 | $794.3M | $530.6M | ||
| Q4 24 | $727.6M | $554.5M | ||
| Q3 24 | $660.9M | $540.1M | ||
| Q2 24 | $608.7M | $532.7M | ||
| Q1 24 | $561.4M | $515.5M |
| Q4 25 | $1.1B | $707.1M | ||
| Q3 25 | $1.1B | $732.6M | ||
| Q2 25 | $971.9M | $731.8M | ||
| Q1 25 | $908.9M | $708.7M | ||
| Q4 24 | $851.4M | $746.4M | ||
| Q3 24 | $772.0M | $734.0M | ||
| Q2 24 | $706.4M | $756.8M | ||
| Q1 24 | $646.7M | $763.6M |
| Q4 25 | — | 0.15× | ||
| Q3 25 | — | 0.15× | ||
| Q2 25 | — | 0.18× | ||
| Q1 25 | — | 0.18× | ||
| Q4 24 | — | 0.18× | ||
| Q3 24 | — | 0.18× | ||
| Q2 24 | — | 0.23× | ||
| Q1 24 | — | 0.27× |
キャッシュフローと資本効率
再投資後に実際に生み出すキャッシュ。純利益より操作が難しい
| 指標 | | |
|---|---|---|
| 営業キャッシュフロー直近四半期 | $44.9M | $20.0M |
| フリーキャッシュフロー営業CF - 設備投資 | $44.9M | $14.9M |
| FCFマージンFCF / 売上 | 29.4% | 6.2% |
| 設備投資強度設備投資 / 売上 | 0.0% | 2.1% |
| キャッシュ転換率営業CF / 純利益 | 0.85× | 1.65× |
| 直近12ヶ月FCF直近4四半期 | — | $68.4M |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $44.9M | $20.0M | ||
| Q3 25 | $32.4M | $33.2M | ||
| Q2 25 | $71.3M | $20.3M | ||
| Q1 25 | $60.0M | $10.1M | ||
| Q4 24 | $70.9M | $16.6M | ||
| Q3 24 | $72.9M | $28.6M | ||
| Q2 24 | $64.1M | $18.7M | ||
| Q1 24 | $31.9M | $15.0M |
| Q4 25 | $44.9M | $14.9M | ||
| Q3 25 | — | $27.6M | ||
| Q2 25 | $71.3M | $17.6M | ||
| Q1 25 | — | $8.4M | ||
| Q4 24 | $70.8M | $13.2M | ||
| Q3 24 | $72.6M | $27.5M | ||
| Q2 24 | $64.1M | $17.6M | ||
| Q1 24 | $31.7M | $13.7M |
| Q4 25 | 29.4% | 6.2% | ||
| Q3 25 | — | 10.7% | ||
| Q2 25 | 48.6% | 7.3% | ||
| Q1 25 | — | 3.8% | ||
| Q4 24 | 49.9% | 6.1% | ||
| Q3 24 | 56.4% | 11.4% | ||
| Q2 24 | 52.3% | 7.8% | ||
| Q1 24 | 32.2% | 6.5% |
| Q4 25 | 0.0% | 2.1% | ||
| Q3 25 | 0.0% | 2.2% | ||
| Q2 25 | 0.0% | 1.1% | ||
| Q1 25 | 0.0% | 0.8% | ||
| Q4 24 | 0.1% | 1.5% | ||
| Q3 24 | 0.2% | 0.5% | ||
| Q2 24 | 0.0% | 0.5% | ||
| Q1 24 | 0.2% | 0.6% |
| Q4 25 | 0.85× | 1.65× | ||
| Q3 25 | 0.61× | 1.36× | ||
| Q2 25 | 1.37× | 1.02× | ||
| Q1 25 | 1.06× | 0.66× | ||
| Q4 24 | 1.27× | 1.15× | ||
| Q3 24 | 1.66× | 1.33× | ||
| Q2 24 | 1.57× | 1.19× | ||
| Q1 24 | 1.37× | 0.71× |
財務フロー比較
売上 → 粗利 → 営業利益 → 純利益のサンキー図
セグメント別売上内訳
CPRX
| Firdapse | $97.6M | 64% |
| Agamree | $35.3M | 23% |
| Fycompa | $19.6M | 13% |
OSW
| Services | $197.3M | 82% |
| Products | $44.8M | 18% |
